肾癌术后联合DC和CIK免疫治疗对患者免疫功能影响

发布时间：2018-12-25 08:46

【摘要】：目的：观察树突状细胞（DC）联合细胞因子诱导的杀伤细胞（CIK）免疫治疗对肾癌术后患者免疫功能的影响。方法：回顾性分析2011年9月至2013年6月期间在我院确诊的52例肾癌患者，均采取肾癌根治性切除手术或保留肾单位手术，术后随访过程中曾予以行DC联合CIK细胞辅助免疫治疗，分别于治疗前一周、治疗后两周，抽取患者外周血采用流式细胞术和酶联免疫吸附法检测患者免疫功能指标，包括外周血CD3+、CD4+、CD8+T淋巴细胞亚群百分比、CD4+/CD8+的比值，以及外周血INF-、IL-2、IL-10等细胞因子水平；同时记录回输过程中的毒副反应，以及评估患者的生活质量。结果：1.治疗后两周外周血CD3+、CD4+T淋巴细胞百分比、CD4+/CD8+的比值、IL-2、INF-水平较治疗前一周升高，2.治疗后两周外周血CD8+T淋巴细胞百分比、IL-10水平较治疗前一周下降，前后两者比较差异均有统计学意义(淋巴细胞比例P0.05，细胞因子P0.01)；3.治疗过程中，毒副反应较少，患者的生活质量较前明显改善。结论：DC联合CIK细胞免疫治疗能显著改善肾癌术后患者的免疫失衡状态，激发特异性免疫应答，提高患者的免疫功能；患者不良反应较少，耐受性良好；可能降低肾癌术后肿瘤的复发率，并且对于转移性肾癌的治疗也显现一定的疗效。
[Abstract]:Aim: to observe the effect of dendritic cell (DC) combined with cytokine induced killer cell (CIK) immunotherapy on immune function of patients with renal cell carcinoma after operation. Methods: from September 2011 to June 2013, 52 patients with renal cell carcinoma diagnosed in our hospital were treated with radical resection of renal cell carcinoma or nephron-sparing surgery. DC combined with CIK cell adjuvant immunotherapy was performed during follow-up. Flow cytometry and enzyme-linked immunosorbent assay (Elisa) were used to detect the immune function, including the percentage of CD3, CD4, CD8 T lymphocyte subsets and the ratio of CD4 / CD8. And the level of cytokines such as INF-,IL-2,IL-10 in peripheral blood; Side effects were also recorded during retransfusion and quality of life was assessed. Results: 1. Two weeks after treatment, the percentage of CD3, CD4 T lymphocytes, the ratio of CD4 / CD8, and the level of IL-2,INF- in peripheral blood were higher than those in the week before treatment. Two weeks after treatment, the percentage of CD8 T lymphocytes and the level of IL-10 in peripheral blood were significantly lower than those before treatment (P 0.05, cytokine P0.01). In the course of treatment, the side effects were less and the quality of life was improved obviously. Conclusion: DC combined with CIK cell immunotherapy can significantly improve the immune imbalance, stimulate specific immune response and improve the immune function of patients with renal cell carcinoma, with less adverse reactions and good tolerance. It may reduce the recurrence rate of renal cell carcinoma after operation, and also show certain curative effect for metastatic renal cell carcinoma.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.11

【参考文献】